Expertise in
5
conditions

Dr. Shyam S. Rao

Neurology
Henry Ford Health System
2799 W Grand Blvd, 
Detroit, MI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
5
conditions
Henry Ford Health System
2799 W Grand Blvd, 
Detroit, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shyam Rao is a Neurologist in Detroit, Michigan. Dr. Rao is highly rated in 5 conditions, according to our data. His top areas of expertise are Delirium, Subarachnoid Hemorrhage, Stroke, Thrombectomy, and Craniectomy. Dr. Rao is currently accepting new patients.

His clinical research consists of co-authoring 76 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in RI
Hospital Affiliations
Henry Ford Health Hospital
Languages Spoken
English
Hindi
Kannada
Tamil
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Priority Health
  • HMO
  • POS

Locations

HENRY FORD HEALTH SYSTEM
2799 W Grand Blvd, Detroit, MI 48202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: November 07, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
View 5 Less Clinical Trials
Similar Doctors
Expertise in
24
conditions
Dr. Tobias Walbert
Neurology
Expertise in
24
conditions
Dr. Tobias Walbert
Neurology

Henry Ford Health System

2799 W Grand Blvd, 
Detroit, MI 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tobias Walbert is a Neurologist in Detroit, Michigan. Dr. Walbert is highly rated in 24 conditions, according to our data. His top areas of expertise are Glioma, Brain Tumor, Glioblastoma, and Astrocytoma.

Expertise in
61
conditions
Dr. Aaron L. Ellenbogen
Neurology
Expertise in
61
conditions
Dr. Aaron L. Ellenbogen
Neurology

Michigan Institute For Neurological Disorders (MIND)

28595 Orchard Lake Road, Suite 200, 
Farmington Hills, MI 
 (17.1 miles away)
248-553-0010
Experience:
28+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aaron Ellenbogen is a Neurologist in Farmington Hills, Michigan. Dr. Ellenbogen has been practicing medicine for over 28 years is highly rated in 61 conditions, according to our data. His top areas of expertise are Movement Disorders, Parkinson's Disease, Drug Induced Dyskinesia, Essential Tremor, and Deep Brain Stimulation. Dr. Ellenbogen is currently accepting new patients.

Expertise in
42
conditions
Dr. Henry L. Paulson
Neurology
Expertise in
42
conditions
Dr. Henry L. Paulson
Neurology

Regents Of The University Of Michigan

4260 Plymouth Rd, U Of M Sleep Medicine, 
Ann Arbor, MI 
 (30.3 miles away)
734-936-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Henry Paulson is a Neurologist in Ann Arbor, Michigan. Dr. Paulson is highly rated in 42 conditions, according to our data. His top areas of expertise are Olivopontocerebellar Atrophy, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia, and Drug Induced Dyskinesia. Dr. Paulson is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rao's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile